ES537909A0 - Procedimiento para la preparacion de anticuerpos contra digitalis - Google Patents

Procedimiento para la preparacion de anticuerpos contra digitalis

Info

Publication number
ES537909A0
ES537909A0 ES537909A ES537909A ES537909A0 ES 537909 A0 ES537909 A0 ES 537909A0 ES 537909 A ES537909 A ES 537909A ES 537909 A ES537909 A ES 537909A ES 537909 A0 ES537909 A0 ES 537909A0
Authority
ES
Spain
Prior art keywords
digitalis
antibodies
immunologically
active
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES537909A
Other languages
English (en)
Spanish (es)
Other versions
ES8600770A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of ES8600770A1 publication Critical patent/ES8600770A1/es
Publication of ES537909A0 publication Critical patent/ES537909A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES537909A 1983-11-26 1984-11-23 Procedimiento para la preparacion de anticuerpos contra digitalis Granted ES537909A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen

Publications (2)

Publication Number Publication Date
ES8600770A1 ES8600770A1 (es) 1985-11-01
ES537909A0 true ES537909A0 (es) 1985-11-01

Family

ID=6215371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES537909A Granted ES537909A0 (es) 1983-11-26 1984-11-23 Procedimiento para la preparacion de anticuerpos contra digitalis

Country Status (8)

Country Link
US (1) US4742159A (enExample)
EP (1) EP0143413B1 (enExample)
JP (1) JPS60132922A (enExample)
AT (1) ATE64141T1 (enExample)
CA (1) CA1242393A (enExample)
DE (2) DE3342870A1 (enExample)
ES (1) ES537909A0 (enExample)
SU (1) SU1455999A3 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH0623761B2 (ja) * 1988-12-09 1994-03-30 株式会社ピーシーシーテクノロジー 配糖化した化合物を生産する細胞の検出方法
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US7348294B2 (en) * 2000-05-25 2008-03-25 Kaneka Corporation Adsorbent and method for adsorbing cardiac glycoside
FR2810667B1 (fr) * 2000-06-23 2004-09-03 Warner Lambert Co Procede d'isolement et de purification d'une proteine, et proteine obtenue
US6802966B2 (en) * 2001-08-14 2004-10-12 W. R. Grace & Co. Conn. Solid compositions for selective adsorption from complex mixtures
US6987079B2 (en) * 2001-08-14 2006-01-17 W.R. Grace & Co.-Conn. Supported catalyst systems
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
CA2745111A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8663637B2 (en) 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
JP7090545B2 (ja) 2015-12-02 2022-06-24 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
EP3436481B1 (en) 2016-03-29 2021-06-30 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
CN109195990A (zh) 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
DE112018005145T5 (de) 2017-09-15 2020-07-23 The Regents Of The University Of California Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
AU2018341454B2 (en) 2017-09-26 2023-09-28 The Regents Of The University Of California Compositions and methods for treating cancer
EP3802616A4 (en) 2018-06-04 2022-03-30 University of Maryland, Baltimore PROCEDURES FOR THE PREVENTION OF AN ACUTE KIDNEY LESION
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790475A (en) * 1972-03-27 1974-02-05 Corning Glass Works Porous glass support material
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4081246A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Solid phase column immunoassay procedure employing novel immunochemical composites
US4081245A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4434234A (en) * 1981-04-02 1984-02-28 The Upjohn Company Method and kit for silver staining substances supported in matrix

Also Published As

Publication number Publication date
JPS60132922A (ja) 1985-07-16
ES8600770A1 (es) 1985-11-01
JPH0324480B2 (enExample) 1991-04-03
ATE64141T1 (de) 1991-06-15
DE3484673D1 (de) 1991-07-11
CA1242393A (en) 1988-09-27
EP0143413B1 (de) 1991-06-05
SU1455999A3 (ru) 1989-01-30
EP0143413A3 (en) 1988-07-20
EP0143413A2 (de) 1985-06-05
DE3342870A1 (de) 1985-06-05
US4742159A (en) 1988-05-03

Similar Documents

Publication Publication Date Title
ES537909A0 (es) Procedimiento para la preparacion de anticuerpos contra digitalis
Kunkel et al. Relation between certain myeloma proteins and normal gamma globulin
Fischer‐Colbrie et al. Isolation and immunological characterization of a glycoprotein from adrenal chromaffin granules
DK96689D0 (da) Fremgangsmaade til immunbestemmelse og diagnostisk middel til anvendelse ved fremgangsmaaden
AU4926085A (en) Immunoassays for protein analytes, particularly HB A1c, involving sample denaturation
SE7909488L (sv) Hemjernrikat aminosyrapreparat och forfarande for framstellning av hemjernrikade aminosyrapreparat fran hemproteiner
Stanislawski-Birencwajg Specific antigens of rat embryonic serum
NZ237535A (en) Carrier for binding anti-phospholipid antibodies, its use in immunoassays and kits and blood protein which enhances binding ability of antiphospholipid antibody
Uriel et al. Affinity chromatography of human, rat and mouse α-fetoprotein on estradiol-sepharose adsorbents
AU564575B2 (en) Polyvalent endotoxin specific antibodies
Knight et al. Papain cleavage of rabbit secretory immunoglobulin A. Differential sensitivity of f and g subclasses
Bøg-Hansen et al. A set of analytical electrophoresis experiments to predict the results of affinity chromatographic separations: fractionation of allergens from cow's hair and dander
Pazur et al. Anti-glycosyl antibodies. Two sets of isoantibodies with specificity for different carbohydrate moieties of the same glycosyl antigen.
Lee et al. Removal of unbound sodium dodecyl sulfate (SDS) from proteins in solution by electrophoresis through Triton X-100-agarose
Kawakita Immunochemical studies on the brain specific protein
Svehag et al. Ultrastructure of papain and pepsin digestion fragments of human IgM globulins
Karamova et al. Conformational variants of human alpha-fetoprotein
Henson et al. Isolation of serum fractions capable of producing Aleutian disease in mink
Palmer Affinity chromatography: Interactions between sepharose-linked and soluble γ-globulin
MacGregor et al. Isolation and characterisation of a surface membrane glycoprotein from adult Schistosoma mansoni
RU2094078C1 (ru) Хроматографический способ выделения альфа-фетопротеина
Davis et al. Diazotized m-aminobenzyloxymethylcellulose as the insoluble matrix for an immunoadsorbent used in the purification of antigens and antibodies
DE3568639D1 (en) Method for the determination of a substance capable of immunological binding
Pasieka et al. Antibody production in goat milk serum after virus instillation of goat mammary gland. V. Biochemical isolation and further characterization of antibodies to various influenza and mumps viruses
Lehrer Isolation of IgE from normal mouse serum

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20050528